STM2457, a potent and selective inhibitor of METTL3 leads to reduced AML growth and an increase in differentiation and apoptosis.24 We have discovered several specific and highly efficient inhibitors targeting FTO to treat leukemia.25 More promisingly, m6A modification also modulates drug resistance and reprograms immune response.26 Therefore, combining such inhibitors targeting m6A machinery with chemotherapy and/or immunotherapy may lead to the development of more effective therapies to overcome therapy resistance and cure leukemia. This evidence concerns the gene METTL3 and leukemia.